T0	KEYPHRASE-NOTYPES 0 8	Patients,"","who"
T1	KEYPHRASE-NOTYPES 25 30	areas," in","whe"
T2	KEYPHRASE-NOTYPES 37 49	Lyme disease,"ere","is "
T3	KEYPHRASE-NOTYPES 77 82	years,"ght","of "
T4	KEYPHRASE-NOTYPES 86 89	age," of","or "
T5	KEYPHRASE-NOTYPES 131 147	Lyme borreliosis,"ted","wer"
T6	KEYPHRASE-NOTYPES 166 176	enrollment,"for","in "
T7	KEYPHRASE-NOTYPES 185 194	openlabel,"his"," co"
T8	KEYPHRASE-NOTYPES 220 237	multicenter study,"ed,"," Th"
T9	KEYPHRASE-NOTYPES 243 248	study,"The","was"
T10	KEYPHRASE-NOTYPES 271 274	May,"een","199"
T11	KEYPHRASE-NOTYPES 284 288	June,"and","199"
T12	KEYPHRASE-NOTYPES 295 311	Erythema migrans,"94."," de"
T13	KEYPHRASE-NOTYPES 347 371	erythematous skin lesion,"ar,","at "
T14	KEYPHRASE-NOTYPES 383 385	cm,"t 5","in "
T15	KEYPHRASE-NOTYPES 389 397	diameter," in"," wa"
T16	KEYPHRASE-NOTYPES 416 427	study entry,"for"," Di"
T17	KEYPHRASE-NOTYPES 442 449	disease,"ted","was"
T18	KEYPHRASE-NOTYPES 480 487	patient,"the","had"
T19	KEYPHRASE-NOTYPES 511 520	following,"the"," mo"
T20	KEYPHRASE-NOTYPES 536 559	erythema migrans lesion,"one"," ca"
T21	KEYPHRASE-NOTYPES 561 569	carditis,"on;","man"
T22	KEYPHRASE-NOTYPES 584 595	heart block," by"," ne"
T23	KEYPHRASE-NOTYPES 597 621	neurologic abnormalities,"ck;","(se"
T24	KEYPHRASE-NOTYPES 623 650	seventh-cranial-nerve palsy,"es ","or "
T25	KEYPHRASE-NOTYPES 654 665	radiculitis," or","of "
T26	KEYPHRASE-NOTYPES 685 701	months duration,"ree","; a"
T27	KEYPHRASE-NOTYPES 708 735	acute large-joint arthritis,"and","\nW"
T28	KEYPHRASE-NOTYPES 737 740	nWe,"is.","exc"
T29	KEYPHRASE-NOTYPES 762 775	nursing women," or","and"
T30	KEYPHRASE-NOTYPES 780 788	patients,"and","wit"
T31	KEYPHRASE-NOTYPES 794 802	evidence,"ith","of "
T32	KEYPHRASE-NOTYPES 806 814	syphilis," of"," me"
T33	KEYPHRASE-NOTYPES 816 826	meningitis,"is,"," or"
T34	KEYPHRASE-NOTYPES 831 856	collagen vascular disease," or"," cu"
T35	KEYPHRASE-NOTYPES 858 874	current symptoms,"se;","of "
T36	KEYPHRASE-NOTYPES 878 890	Lyme disease," of","for"
T37	KEYPHRASE-NOTYPES 930 939	treatment,"ved"," a "
T38	KEYPHRASE-NOTYPES 962 969	disease,"ing","tha"
T39	KEYPHRASE-NOTYPES 989 999	evaluation,"the","of "
T40	KEYPHRASE-NOTYPES 1007 1015	response,"the","to "
T41	KEYPHRASE-NOTYPES 1019 1028	treatment," to"," ga"
T42	KEYPHRASE-NOTYPES 1030 1049	gallbladder disease,"nt;"," or"
T43	KEYPHRASE-NOTYPES 1054 1070	hypersensitivity," or","to "
T44	KEYPHRASE-NOTYPES 1074 1085	ceftriaxone," to","or "
T45	KEYPHRASE-NOTYPES 1089 1100	doxycycline," or"," Pa"
T46	KEYPHRASE-NOTYPES 1102 1110	Patients,"ne.","tre"
T47	KEYPHRASE-NOTYPES 1124 1144	antimicrobial agents,"ith","eff"
T48	KEYPHRASE-NOTYPES 1158 1170	Lyme disease," in","wit"
T49	KEYPHRASE-NOTYPES 1181 1186	hours," 48","bef"
T50	KEYPHRASE-NOTYPES 1194 1205	study entry,"ore","or "
T51	KEYPHRASE-NOTYPES 1225 1249	investigational compound," an","wit"
T52	KEYPHRASE-NOTYPES 1261 1266	weeks,"two","bef"
T53	KEYPHRASE-NOTYPES 1274 1285	study entry,"ore","wer"
T54	KEYPHRASE-NOTYPES 1314 1322	patients,"ere","wit"
T55	KEYPHRASE-NOTYPES 1328 1338	meningitis,"ith","or "
T56	KEYPHRASE-NOTYPES 1342 1354	encephalitis," or",""
